Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter
Professionals >> Visit The Body PROThe Body en Espanol
Home Page for TheBody.com, the Complete HIV/AIDS Resource What's New About HIV Ask the Experts About HIV HIV/AIDS Blogs Connect With Others About HIV Just Diagnosed With HIV HIV Treatment HIV Prevention Living With HIV Personal Stories of People With HIV
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

ACTU Study for People Experiencing Protease Inhibitor Failure

From Seattle Treatment Education Project

March 31, 2000

The University of Washington AIDS Clinical Trials Unit has a new study for people who are experiencing protease inhibitor failure of specific drugs within that class. Eligible people will include:

  • People who are experiencing failure of amprenavir, nelfinavir, saquinavir, or nelfinavir/saquinavir combination.

  • Have detectable viral load in the 500 to 100,000 range on the failing protease inhibitor therapy.

  • Have no high-level genotype resistance to the drugs indinavir or ritonavir.

Advertisement
People selected for the study will be given indinavir and ritonavir in two dose combinations (given twice daily) and must be on two nucleoside analogs prescribed by their primary care provider. (The study supplies the protease inhibitors, the participant supplies their own nucleoside analogs.)

If you are interested in this study, and want to find out more about eligibility, you may contact Margot Perrin, Karen Novak, or Carol Glenn at the ACTU. Their phone number is 206-731-3184. Be sure to reference study number 5055 when you call.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.
 
 

Advertisement